A phase 2 multicentre study of siltuximab, an anti‐interleukin‐6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma

No abstract is available for this paper.

• Publication year

  2013

• Venue

  British Journal of Haematology

• Publication date

  2013-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bjh.12266PMID 23432640PMCID PMC5837861
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A phase 2, randomized, double‐blind, placebo‐controlled study of siltuximab (anti‐IL‐6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma

  2015cited by this paper
• Phase II, randomized, double blind, placebo-controlled study comparing siltuximab plus bortezomib versus bortezomib alone in pts with relapsed/refractory multiple myeloma.

  2012cited by this paper
• Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

  2011cited by this paper
• Long-Term Safety in a Phase 1 Study of Siltuximab (CNTO 328), an Anti-Interleukin-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease,

  2011cited by this paper
• Blockade of interleukin‐6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma

  2011cited by this paper
• A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer

  2010cited by this paper
• Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.

  2010cited by this paper
• Pharmacokinetic and Pharmacodynamic Modeling of an Anti–Interleukin-6 Chimeric Monoclonal Antibody (Siltuximab) in Patients with Metastatic Renal Cell Carcinoma

  2010cited by this paper
• A High-Affinity Fully Human Anti–IL-6 mAb, 1339, for the Treatment of Multiple Myeloma

  2009cited by this paper
• Targeted inhibition of interleukin‐6 with CNTO 328 sensitizes pre‐clinical models of multiple myeloma to dexamethasone‐mediated cell death

  2009cited by this paper
• The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma

  2008cited by this paper
• Clinically relevant end points and new drug approvals for myeloma

  2008cited by this paper
• International uniform response criteria for multiple myeloma

  2007cited by this paper
• Inhibition of Interleukin-6 Signaling with CNTO 328 Enhances the Activity of Bortezomib in Preclinical Models of Multiple Myeloma

  2007cited by this paper
• International uniform response criteria for multiple myeloma

  2006cited by this paper
• Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.

  2006cited by this paper
• International uniform response criteria for multiple myeloma

  2006cited by this paper
• Combination Therapy with Interleukin-6 Receptor Superantagonist Sant7 and Dexamethasone Induces Antitumor Effects in a Novel SCID-hu In vivo Model of Human Multiple Myeloma

  2005cited by this paper
• Clinical course of patients with relapsed multiple myeloma.

  2004cited by this paper
• IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin.

  2004cited by this paper
• BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.

  2004cited by this paper
• The IL‐6 receptor antagonist SANT‐7 overcomes bone marrow stromal cell–mediated drug resistance of multiple myeloma cells

  2001cited by this paper
• The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro

  2001cited by this paper
• Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan.

  2000cited by this paper
• Interferon-α protects myeloma cell lines from dexamethasone-induced apoptosis

  1999cited by this paper
• Interferon-alpha protects myeloma cell lines from dexamethasone-induced apoptosis.

  1999cited by this paper
• IFN-alpha is a survival factor for human myeloma cells and reduces dexamethasone-induced apoptosis.

  1998cited by this paper
• Chimaeric anti‐interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose‐escalating study

  1998cited by this paper
• CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION

  1998cited by this paper
• The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone.

  1998cited by this paper
• Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism

  1997cited by this paper
• Multiple myeloma cells are protected against dexamethasone‐induced apoptosis by insulin‐like growth factors

  1997cited by this paper
• Interleukin-6 inhibits apoptosis of malignant plasma cells.

  1995cited by this paper
• The gp 130 family cytokines IL‐6, LIF and OSM but not IL‐11 can reverse the anti‐proliferative effect of dexamethasone on human myeloma cells

  1995cited by this paper
• Interleukin-6 prevents dexamethasone-induced myeloma cell death.

  1994cited by this paper
• Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion.

  1993cited by this paper
• Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6.

  1989cited by this paper
• Response patterns of purified myeloma cells to hematopoietic growth factors.

  1989cited by this paper
• Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas

  1988cited by this paper

• The tumor microenvironment in hematologic malignancies: immune evasion, metabolic reprogramming, and therapeutic resistance.

  2026cites this paper
• Targeting inflammation as cancer therapy

  2024cites this paper
• Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery

  2024cites this paper
• Acquired Bortezomib Resistance in Multiple Myeloma: From Mechanisms to Strategy.

  2024cites this paper
• Therapeutic potential of single-nucleotide polymorphism-mediated interleukin-6 receptor blockade in cancer treatment: A Mendelian randomization study

  2023cites this paper
• Immune-epigenetic crosstalk in haematological malignancies

  2023cites this paper
• Optimizing high dose melphalan.

  2023cites this paper
• Mesenchymal stromal cell senescence in haematological malignancies

  2023cites this paper
• Monocyte and Macrophage in Neuroblastoma: Blocking Their Pro-Tumoral Functions and Strengthening Their Crosstalk with Natural Killer Cells

  2023cites this paper
• Metabolic changes underlying drug resistance in the multiple myeloma tumor microenvironment

  2023cites this paper
• Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment

  2022cites this paper
• Ex vivo propagation in a novel 3D high-throughput co-culture system for multiple myeloma

  2022cites this paper
• Small secretory proteins of immune cells can modulate gynecological cancers.

  2022cites this paper
• Host-microbe interactions and outcomes in multiple myeloma and hematopoietic stem cell transplantation

  2022cites this paper
• Interleukin-6 and indoleamine-2,3-dioxygenase as potential adjuvant targets for Papillomavirus-related tumors immunotherapy

  2022cites this paper
• IONIZING RADIATION AND CYTOKINES: THE ROLE IN THE PATHOGENESIS OF PLASMA CELL MYELOMA (LITERATURE REVIEW).

  2022cites this paper
• Monoclonal Antibodies in Myeloma

  2021influential citation
• Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?

  2021cites this paper
• Therapeutic outcome of early-phase clinical trials in multiple myeloma: a meta-analysis

  2021cites this paper
• Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets

  2021cites this paper
• 白细胞介素-6相关抗体治疗多发性骨髓瘤的研究进展

  2021cites this paper
• Autophagic degradation of NOXA underlies stromal cell-mediated resistance to proteasome inhibitors in mantle cell lymphoma.

  2021cites this paper
• Treatment Strategies Considering Micro-Environment and Clonal Evolution in Multiple Myeloma

  2021cites this paper
• Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40

  2021cites this paper
• Tackling SARS-CoV-2: proposed targets and repurposed drugs

  2020cites this paper
• Herpesvirus Infections Potentiated by Biologics.

  2020cites this paper
• Co-activation of NF-κB and MYC renders cancer cells addicted to IL6 for survival and phenotypic stability

  2020cites this paper
• Therapeutic targets in myeloma bone disease

  2020cites this paper
• IL-6 Blockade Limitations as an Anticancer Strategy: Literature Review and Proposal of Explanations for Unexpected Results

  2020cites this paper
• Immunotherapy in Multiple Myeloma

  2020cites this paper
• Current antibody-based therapies for the treatment of multiple myeloma.

  2020cites this paper
• Contribution of the bone marrow stromal cells in mediating drug resistance in hematopoietic tumors.

  2020cites this paper
• The long non-coding RNA CRNDE regulates growth of multiple myeloma cells via an effect on IL6 signalling

  2020cites this paper
• Immune-based therapies in the management of multiple myeloma

  2020cites this paper
• Role of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance.

  2020cites this paper
• Natural Sesquiterpene Lactones Enhance Chemosensitivity of Tumor Cells through Redox Regulation of STAT3 Signaling

  2019cites this paper
• Interleukin-6 Interweaves the Bone Marrow Microenvironment, Bone Loss, and Multiple Myeloma

  2019cites this paper
• Cytokine-targeted therapy for the management of solid organ transplant recipients.

  2019cites this paper
• IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplification

  2019cites this paper
• Potential Relationship between Clinical Significance and Serum Exosomal miRNAs in Patients with Multiple Myeloma

  2019cites this paper
• Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets

  2019cites this paper
• The emergence of drug resistance to targeted cancer therapies: Clinical evidence.

  2019cites this paper
• The impact of the bone marrow microenvironment on multiple myeloma (Review).

  2019cites this paper
• Apigenin Inhibits IL-6 Transcription and Suppresses Esophageal Carcinogenesis

  2019cites this paper
• Role of The Osteoclast in Cancer

  2019cites this paper
• Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development

  2019cites this paper
• Modulation of the IL-6-Signaling Pathway in Liver Cells by miRNAs Targeting gp130, JAK1, and/or STAT3

  2019cites this paper
• Cytokines, breast cancer stem cells (BCSCs) and chemoresistance

  2018cites this paper
• The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer.

  2018cites this paper
• Multiple Myeloma: Personalised Medicine Based on Pathogenesis

  2018cites this paper
• Immunotherapy: A Novel Era of Promising Treatments for Multiple Myeloma

  2018cites this paper
• Proteasome Inhibitors with a Focus on Bortezomib

  2018cites this paper
• The role of the interleukin (IL)-6/IL-6 receptor axis in cancer.

  2018cites this paper
• Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma

  2018cites this paper
• Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update

  2018cites this paper
• Resistance Mechanisms to Novel Therapies in Myeloma

  2018cites this paper
• Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma

  2018cites this paper
• Resistance to proteasome inhibitors and other targeted therapies in myeloma

  2018cites this paper
• Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment.

  2018cites this paper
• Resistance of Targeted Therapies Excluding Antibodies for Lymphomas

  2018cites this paper
• Tumor Hypoxia As an Enhancer of Inflammation-Mediated Metastasis: Emerging Therapeutic Strategies

  2018cites this paper
• Effects of human umbilical cord-derived mesenchymal stem cells on hematologic malignancies

  2018cites this paper
• Interleukin-6: designing specific therapeutics for a complex cytokine

  2018cites this paper
• Targeting the IL-6/JAK/STAT3 signalling axis in cancer

  2018cites this paper
• Glucocorticoids in multiple myeloma: past, present, and future

  2018cites this paper
• Precision Medicine in Myeloma: Challenges in Defining an Actionable Approach

  2017cites this paper
• Immune‐suppressive effects of interleukin‐6 on T‐cell‐mediated anti‐tumor immunity

  2017cites this paper
• Monoclonal antibody therapy in multiple myeloma

  2017cites this paper
• Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.

  2017cites this paper
• Emerging immune targets for the treatment of multiple myeloma.

  2017cites this paper
• ENabling Reduction of Low‐grade Inflammation in SEniors Pilot Study: Concept, Rationale, and Design

  2017cites this paper
• Interleukin‐6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy

  2017cites this paper
• Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth

  2017cites this paper
• Anti-Interleukin-6 Promotes Allogeneic Bone Marrow Engraftment and Prolonged Graft Survival in an Irradiation-Free Murine Transplant Model

  2017cites this paper
• Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.

  2017cites this paper
• Tumor-associated macrophages promote neuroblastoma via STAT3 phosphorylation and up-regulation of c-MYC

  2017cites this paper
• Repositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapy

  2017cites this paper
• Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma

  2017cites this paper
• Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma

  2017cites this paper
• Gr upSM Interleukin-6 as a Therapeutic Target on Human Cancer

  2017cites this paper
• Rôle de la molécule APRIL dans le développement des hémopathies malignes B

  2017cites this paper
• Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma.

  2017cites this paper
• Monoclonal antibodies - A new era in the treatment of multiple myeloma.

  2016cites this paper
• Revisiting IL-6 antagonism in multiple myeloma.

  2016cites this paper
• Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma

  2016cites this paper
• Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma

  2016cites this paper
• Hormonal-receptor positive breast cancer: IL-6 augments invasion and lymph node metastasis via stimulating cathepsin B expression☆

  2016cites this paper
• Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease.

  2016cites this paper
• IL-6 down-regulates HLA class II expression and IL-12 production of human dendritic cells to impair activation of antigen-specific CD4+ T cells

  2016cites this paper
• Emerging antibodies for the treatment of multiple myeloma

  2016cites this paper
• T-Cell Immunity to Influenza in Older Adults: A Pathophysiological Framework for Development of More Effective Vaccines

  2016cites this paper
• Development of Novel Immunotherapies for Multiple Myeloma

  2016cites this paper
• Classical and non-classical proangiogenic factors as a target of antiangiogenic therapy in tumor microenvironment.

  2016cites this paper
• An inhibitor of cholesterol absorption displays anti-myeloma activity by targeting the JAK2-STAT3 signaling pathway

  2016cites this paper
• Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial

  2016cites this paper
• Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer

  2016cites this paper
• Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis.

  2016cites this paper
• Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins

  2016cites this paper
• Immunization against an IL-6 peptide induces anti-IL-6 antibodies and modulates the Delayed-Type Hypersensitivity reaction in cynomolgus monkeys

  2016cites this paper
• Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?

  2016cites this paper